Δnp63 regulates select routes of reprogramming via multiple mechanisms

Cell Death and Differentiation

Volumn 20, Issue 12, 2013, Pages 1698-1708

  Alexandrova, E M ^a   Petrenko, O ^a   Nemajerova, A ^a   Romano, R A ^b   Sinha, S ^b   Moll, U M ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Np63; iPSCs; p63; pluripotency; reprogramming

Indexed keywords

KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P53; PROTEIN P63; PROTEIN P73; TRANSCRIPTION FACTOR SOX2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL POPULATION; CELL PROLIFERATION; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE CONTROL; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; CELL PROLIFERATION; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE EXPRESSION REGULATION; INDUCED PLURIPOTENT STEM CELLS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; NUCLEAR REPROGRAMMING; OCTAMER TRANSCRIPTION FACTOR-3; PHOSPHOPROTEINS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MET; SOXB1 TRANSCRIPTION FACTORS; TRANS-ACTIVATORS; UP-REGULATION;

EID: 84887625156     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.122     Document Type: Article

References (58)

1. Stadtfeld M, Hochedlinger K. Induced pluripotency: History, mechanisms, and applications. Genes Dev 2010; 24: 2239-2263.
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676. (Pubitemid 44233629)
3. Wernig M, Meissner A, Cassady JP, Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2008; 2: 10-12.
4. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotech 2008; 26: 101-106.
5. Martinez-Fernandez A, Nelson TJ, Ikeda Y, Terzic A. c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells. J Cardiovasc Transl Res 2010; 3: 13-23.
6. Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008; 454: 646-650.
7. Kim JB, Greber B, Araúzo-Bravo MJ, Meyer J, Park KI, Zaehres H et al. Direct reprogramming of human neural stem cells by OCT4. Nature 2009; 461: 649-643.
8. Kim JB, Sebastiano V, Wu G, Araúzo-Bravo MJ, Sasse P, Gentile L et al. Oct4-induced pluripotency in adult neural stem cells. Cell 2009; 136: 411-419.
9. Hester ME, Song S, Miranda CJ, Eagle A, Schwartz PH, Kaspar BK. Two factor reprogramming of human neural stem cells into pluripotency. PLoS One 2009; 4: E7044.
10. Nemajerova A, Kim SY, Petrenko O, Moll UM. Two-factor reprogramming of somatic cells to pluripotent stem cells reveals partial functional redundancy of Sox2 and Klf4. Cell Death Differ 2012; 19: 1268-1276.
11. Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010; 7: 64-77.
12. Buganim Y, Faddah DA, Cheng AW, Itskovich E, Markoulaki S, Ganz K et al. Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 2012; 150: 1209-1222.
13. Smith ZD, Nachman I, Regev A, Meissner A. Dynamic single-cell imaging of direct reprogramming reveals an early specifying event. Nat Biotechnol 2010; 28: 521-526.
14. Li R, Liang J, Ni S, Zhou T, Qing X, Li H et al. A mesenchymal-to- epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010; 7: 51-63.
15. Chen J, Liu J, Yang J, Chen Y, Chen J, Ni S et al. BMPs functionally replace Klf4 and support efficient reprogramming of mouse fibroblasts by Oct4 alone. Cell Res 2011; 21: 205-212.
16. Hanna J, Carey BW, Jaenisch R. Reprogramming of somatic cell identity. Cold Spring Harb Symp Quant Biol 2008; 73: 147-155.
17. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: Facts, hypotheses, unresolved issues. Cell 2010; 143: 508-525.
18. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012; 119: 3668-3683.
19. Talos F, Moll UM. Role of the p53 family in stabilizing the genome and preventing polyploidization. Adv Exp Med Biol 2010; 676: 73-91.
20. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta 2009; 1787: 414-420.
21. Zhao Y, Yin X, Qin H, Zhu F, Liu H, Yang W et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 2008; 3: 475-479.
22. Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009; 460: 1149-1153.
23. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009; 460: 1145-1148.
24. Li H, Collado M, Villasante A, Strati K, Ortega S, Canãmero M et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009; 460: 1136-1139.
25. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460: 1140-1144.
26. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009; 460: 1132-1135.
27. Ye D, Wang G, Liu Y, Huang W, Wu M, Zhu S et al. MiR-138 promotes induced pluripotent stem cell generation through the regulation of the p53 signaling. Stem Cells 2012; 30: 1645-1654.
28. Hanna J, Saha K, Pando B, Van Zon J, Lengner CJ, Creyghton MP et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 2009; 462: 595-601.
29. Brosh R, Assia-Alroy Y, Molchadsky A, Bornstein C, Dekel E, Madar S et al. p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death Differ 2013; 20: 312-320.
30. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708-713. (Pubitemid 29197649)
31. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714-718. (Pubitemid 29197650)
32. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404: 99-103. (Pubitemid 30143141)
33. Talos F, Abraham A, Vaseva AV, Holembowski L, Tsirka SE, Scheel A et al. p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis. Cell Death Differ 2010; 17: 1816-1829.
34. Alexandrova EM, Talos F, Moll UM. p73 is dispensable for commitment to neural stem cell fate, but is essential for neural stem cell maintenance and for blocking premature differentiation. Cell Death Diff 2013; 20: 368.
35. Alexandrova EM, Moll UM. Role of p53 family members p73 and p63 in human hematological malignancies. Leuk Lymphoma 2012; 53: 2116-2129.
36. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV et al. p73 in cancer. Genes Cancer 2011; 2: 491-502.
37. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Diff 2011; 18: 1487-1499.
38. Lin Y, Cheng Z, Yang Z, Zheng J, Lin T. DNp73 improves generation efficiency of human induced pluripotent stem cells. BMC Cell Biol 2012; 13: 9.
39. Su X, Cho MS, Gi YJ, Ayanga BA, Sherr CJ, Flores ER. Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf. EMBO J 2009; 28: 1904-1915.
40. He L, He X, Lim LP, De Stanchina E, Xuan Z, Liang Y et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-1134. (Pubitemid 47014436)
41. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol 2011; 13: 1353-1360.
42. Antonini D, Russo MT, De Rosa L, Gorrese M, Del Vecchio L, Missero C. Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells. J Invest Dermatol 2010; 130: 1249-1257.
43. Lake BB, Fink J, Klemetsaune L, Fu X, Jeffers JR, Zambetti GP et al. Context-dependent enhancement of induced pluripotent stem cell reprogramming by silencing Puma. Stem Cells 2012; 30: 888-897.
44. Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, Mueller M et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 2007; 6: 274-285.
45. Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev 2006; 20: 3185-3197. (Pubitemid 44790632)
46. Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, Paradisi A et al. Differential roles of p63 isoforms in epidermal development: Selective genetic complementation in p63 null mice. Cell Death Differ 2006; 13: 1037-1047.
47. Koster MI, Dai D, Marinari B, Sano Y, Costanzo A, Karin M et al. p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci USA 2007; 104: 3255-3260. (Pubitemid 46364146)
48. Romano RA, Smalley K, Magraw C, Serna VA, Kurita T, Raghavan S et al. DNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development 2012; 139: 772-782.
49. Su X, Paris M, Gi YJ, Tsai KY, Cho MS, Lin YL et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell 2009; 5: 64-75.
50. Grob TJ, Novak U, Maisse C, Barcaroli D, Lüthi AU, Pirnia F et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001; 8: 1213-1223. (Pubitemid 34048476)
51. Jaubert J, Cheng J, Segre JA. Ectopic expression of kruppel like factor 4 (Klf4) accelerates formation of the epidermal permeability barrier. Development 2003; 130: 2767-2777. (Pubitemid 37069591)
52. Segre JA, Bauer C, Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. Nat Genet 1999; 22: 356-360. (Pubitemid 29369526)
53. Dai X, Segre JA. Transcriptional control of epidermal specification and differentiation. Curr Opin Genet Dev 2004; 14: 485-491. (Pubitemid 39360294)
54. Cordani N, Pozzi S, Martynova E, Fanoni D, Borrelli S, Alotto D et al. Mutant p53 subverts p63 control over KLF4 expression in keratinocytes. Oncogene 2011; 30: 922-932.
55. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7.
56. Alexandrova EM, Moll UM. Generation of p53-deficient induced pluripotent stem cells from mouse embryo fibroblasts. Methods Mol Biol 2013; 962: 157-164.
57. Wolff S, Talos F, Palacios G, Beyer U, Dobbelstein M, Moll UM. The alpha/beta carboxyterminal domains of p63 are required for skin and limb development. New insights from the Brdm2 mouse which is not a complete p63 knockout but expresses p63 gamma-like proteins. Cell Death Differ 2009; 16: 1108-1117.
58. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37: 1289-1295. (Pubitemid 41568715)